Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
Miguel Martín(Hospital General Universitario Gregorio Marañón), Noelia Jáñez Martínez, Hiroji Iwata(Aichi Cancer Center), Robert Šeparović(University Hospital Centre Zagreb), William Graydon Harker, A. Ciceniene(Vilnius University), Z. Tomasevic(Oncology Institute of Vojvodina), Beverly Moy(Global Cancer Institute), Rudolf Tomek, Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Sung‐Bae Kim(Ulsan College), Frankie A. Holmes(Texas Oncology), Anil A. Joy(University of Alberta), Bent Ejlertsen, Katarína Petráková(Masaryk Memorial Cancer Institute), Ángel Guerrero‐Zotano(Fundación Instituto Valenciano de Oncología), John W. Smith(SUNY Upstate Medical University), Friedrich Overkamp, Ira Gore(St. Vincent's Birmingham), Anne Armstrong(The Christie NHS Foundation Trust), Joan B. Heijns(Amphia Ziekenhuis), Anna Bashford(Auckland City Hospital), Norikazu Masuda(Kyoto University), Erik Jakobsen(Aarhus University Hospital), Nicholas Iannotti, Zora Neskovic Konstantinovic, Gladys Rodriguez, Nicholas J. Robert(Tufts Medical Center), Pierfrancesco Tassone(Magna Graecia University), John S. Link, Erhan Gökmen(Ege University), Stephen Chia(BC Cancer Agency), Susan Moran(QED Technologies (United States)), Suzette Delaloge(Institut Gustave Roussy), Richard Bryce(Puma Biotechnology (United States)), Marc Buyse(Institut des Arts de Diffusion), Alvin Wong(Puma Biotechnology (United States)), Neelima Denduluri(Washington Hospital), Bin Yao(Puma Biotechnology (United States)), Kenichi Inoue(Universitair Ziekenhuis Leuven), Feng Xu(North Sichuan Medical University), Carlos H. Barrios(Eastern Cooperative Oncology Group), S. Di Sean Kendall, Vernon Harvey(Auckland City Hospital), Gϋnter von Minckwitz(German Breast group), Janine Mansi(Guy's and St Thomas' NHS Foundation Trust), Manuel Ruíz Borrego(Hospital Universitario Virgen del Rocío), Arlene Chan(Curtin University), Amparo Ruiz Simón, Alan Auerbach(Puma Biotechnology (United States))
Cited by 594
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k